Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

IXICO names new non-executive director

Rogers previously held senior positions at GlaxoSmithKline

IXICO PLC (AIM:IXI, OTC:PHYOF) said Kate Rogers has joined as non-executive director and chair of the audit committee to replace John Bradshaw, who will be leaving the company in April.

Rogers currently leads the transformation of GlaxoSmithKline's (GSK) global finance organisation, having worked as chief financial officer for Laboratoire GlaxoSmithKline SaS (GSK France), and other senior finance roles within GSK.

“We are delighted to welcome Kate to IXICO and look forward to benefitting from her broad and deep experience of both the pharmaceutical sector and international finance,” said Charles Spicer, chair of the board.

Rodgers replaces the retiring Bradshaw, who has served as director and chair of the audit committee of the data analytics company since 2013.

“I would like to thank John for the outstanding contribution he has made to IXICO over the last nine years. His support for the company and wise advice to us all has been invaluable,” Spicer added.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK